ERBB2 and breast carcinoma: Neoadjuvant treatment for TN and HER2+ breast cancer has evidently changed over time, with rates of pre-treatment medical oncology consultation increasing from 28.6% to 40.8% and those of NAC from 22.8% to 32.5% between 2012–2018 and 2019–2020.